Preclinical safety pharmacology studies on the rapid-acting insulin analogue insulin aspart

Arzneimittel-Forschung/Drug Research

Volumn 49, Issue 5, 1999, Pages 463-470

  Dall, Vivi ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

CAS 116094 23 6; Insulin; Insulin aspart, safety pharmacology; Insulin, analogue, soluble human

Indexed keywords

INSULIN ASPART; INSULIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CAT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SAFETY; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVENOUS DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; THERMOREGULATION;

EID: 0032976894     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300443     Document Type: Article

References (7)

1. Vølund, A., Brange, J., Drejer, K. et al., In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet. Med. 8, 839 (1991)
2. Barnett, A.H., Owens, D.R., Insulin analogues. Lancet 349, 47 (1997)
3. Brange, J., Owens, D.R., Kang, S. et al., Monomeric insulins and their experimental and clinical implications. Diabetes Care 13, 923 (1990)
4. Heinemann, L., Heise, T., Jorgensen, L.N. et al., Action profile of the rapid acting insulin analogue B28Asp. Diabet. Med. 10, 535 (1993)
5. Heinemann, L., Weyer, C., Rave, K. et al., Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28Asp. Exp. Clin. Endocrinol. Diabetes 105, 140 (1997)
6. McKinley, E.R., Williams, P.D., Turk, J.A., Toxicology Report No. 22, Lilly Research Laboratories, Indianapolis, USA (1989)
7. Helton, D.R., Zimmermann, J.L., Heim, A. et al., General pharmacology of insulin lispro in animals. Arzneim.-Forsch./Drug Res. 46 (I), 91 (1996)